Previous studies have observed a significant comorbidity between Alzheimer's disease (AD) and some other neuropsychiatric disorders. However, the mechanistic connections between neuropsychiatric disorders and AD are not well understood. We conducted a Mendelian randomization analysis to appraise the potential influences of 18 neurodegenerative and neuropsychiatric disorders on AD. We found that four disorders are causally associated with increased risk for AD, including bipolar disorder (BD) (OR: 1.09), migraine (OR: 1.09), schizophrenia (OR: 1.05), and Parkinson's disease (PD) (OR: 1.07), while attention-deficit/hyperactivity disorder (ADHD) was associated with a decreased risk for AD (OR: 0.80). In case of amyotrophic lateral sclerosis (OR: 1.04) and Tourette's syndrome (OR: 1.05), there was suggestive evidence of their causal effects of on AD. Our study shows that genetic components predisposing to BD, migraine, schizophrenia, and PD may promote the development of AD, while ADHD may be associated with a reduced risk of AD. The treatments aimed at alleviating neuropsychiatric diseases with earlier onset may also influence the risk of AD-related cognitive decline, which is typically observed later in life.
Int J Geriatr Psychiatry. 2019 Nov;34(11):1667-1676
[PMID:
31486140]
Nat Genet. 2019 Mar;51(3):394-403
[PMID:
30804565]
Gen Psychiatr. 2023 Mar 13;36(2):e100996
[PMID:
36937092]
Am J Psychiatry. 2019 Mar 1;176(3):217-227
[PMID:
30818990]
Mol Psychiatry. 2018 May;23(5):1181-1188
[PMID:
28761083]
J Psychiatr Res. 2023 Jun;162:1-10
[PMID:
37060872]
Nat Genet. 2018 Apr;50(4):524-537
[PMID:
29531354]
Transl Psychiatry. 2019 Oct 22;9(1):273
[PMID:
31641104]
NPJ Parkinsons Dis. 2023 Apr 28;9(1):70
[PMID:
37117178]
Nat Genet. 2022 Apr;54(4):412-436
[PMID:
35379992]
JAMA Psychiatry. 2015 Nov;72(11):1095-101
[PMID:
26444987]
Mol Psychiatry. 2023 Mar;28(3):1248-1255
[PMID:
36476732]
Psychiatry Res. 2022 Aug;314:114679
[PMID:
35717853]
Curr Neuropharmacol. 2019;17(11):1071-1095
[PMID:
31161981]
Nat Genet. 2019 Mar;51(3):431-444
[PMID:
30804558]
Neurol Genet. 2022 Feb 01;8(1):e653
[PMID:
35128049]
Int J Epidemiol. 2019 Jun 1;48(3):728-742
[PMID:
30561657]
Adv Clin Chem. 2019;90:81-132
[PMID:
31122612]
Hum Genet. 2020 Feb;139(2):185-198
[PMID:
31813014]
Nat Neurosci. 2018 Dec;21(12):1656-1669
[PMID:
30482948]
Lancet Neurol. 2019 Dec;18(12):1091-1102
[PMID:
31701892]
Nature. 2022 Apr;604(7906):502-508
[PMID:
35396580]
Nat Commun. 2019 Oct 8;10(1):4558
[PMID:
31594949]
Int J Epidemiol. 2015 Apr;44(2):512-25
[PMID:
26050253]
Hum Mol Genet. 2022 Apr 22;31(8):1336-1345
[PMID:
34761251]
Nat Commun. 2018 Dec 10;9(1):5269
[PMID:
30531953]
BMC Neurol. 2021 Aug 12;21(1):312
[PMID:
34384369]
J Clin Invest. 2022 Feb 1;132(3):
[PMID:
33905376]
Neuron. 2018 Mar 21;97(6):1268-1283.e6
[PMID:
29566793]
JAMA. 2017 Nov 21;318(19):1925-1926
[PMID:
29164242]
J Med Virol. 2023 Jan;95(1):e28264
[PMID:
36316288]
Nat Genet. 2023 Feb;55(2):198-208
[PMID:
36702997]
World Psychiatry. 2021 Oct;20(3):417-436
[PMID:
34505386]
Nat Neurosci. 2019 Mar;22(3):343-352
[PMID:
30718901]
Front Neurosci. 2019 Mar 13;13:220
[PMID:
30930738]
Nat Genet. 2022 Feb;54(2):152-160
[PMID:
35115687]
Nat Genet. 2019 Aug;51(8):1207-1214
[PMID:
31308545]
Adv Exp Med Biol. 2019;1184:187-203
[PMID:
32096039]
Science. 2019 Sep 27;365(6460):
[PMID:
31604244]
QJM. 2023 Oct 6;116(9):766-773
[PMID:
37286376]
J Alzheimers Dis. 2021;83(1):269-279
[PMID:
34308904]
Schizophr Bull. 2021 Jan 23;47(1):197-206
[PMID:
32681179]
Compr Psychiatry. 1996 May-Jun;37(3):188-95
[PMID:
8732586]
Schizophr Bull. 2023 Mar 15;49(2):428-443
[PMID:
36124769]
Front Neurol. 2017 Dec 11;8:670
[PMID:
29321759]
Mol Psychiatry. 2016 Oct;21(10):1485
[PMID:
26857599]
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jan 10;112:110410
[PMID:
34339760]
Nat Genet. 2021 Jun;53(6):817-829
[PMID:
34002096]
Gen Psychiatr. 2023 Apr 5;36(2):e101006
[PMID:
37066117]
